Wisconsin Hospital Becomes First to Implement New Nitric Oxide Delivery System
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
Tag: Mallinckrodt
All
Latest
Wisconsin Hospital Becomes First to Implement New Nitric Oxide Delivery System
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
Read More
Mallinckrodt Expands Rollout of INOmax Evolve DS
Mallinckrodt has begun a national rollout of the INOmax Evolve DS delivery system, which is FDA-cleared to provide inhaled nitric oxide to certain neonatal ICU patients in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation.
Read More
FDA Clears INOmax Evolve DS
The INOmax Evolve DS is Mallinckrodt’s next-generation nitric oxide delivery system that includes a primary delivery system, a monitoring system, an electronic blender, automated backup delivery, mini-cylinders, and more.
Read More
Positive Data on Clinical, Economic Impact of Acthar Gel
Research reinforced the efficacy and safety of Acthar Gel, an FDA-approved therapy for autoimmune and inflammatory diseases like sarcoidosis.
Read More
Mallinckrodt Recalls One-Way Valve Due to Ventilation Interruption Risk
Mallinckrodt Manufacturing is recalling its one-way valve, 22F x 22M, due to devices not opening properly, which prevents or reduces the flow of ventilated air or oxygen.
Read More
Mallinckrodt Submits iNO Delivery System for FDA Clearance
Mallinckrodt plc reports the submission of a 510(k) premarket notification application to the US FDA for an investigational inhaled nitric oxide delivery system for INOmax (nitric oxide) gas, for inhalation.
Read More
Acthar Gel Improved Symptoms in African Americans with Sarcoidosis
A majority of African American patients with symptomatic sarcoidosis treated with Acthar Gel saw clinical improvement in a number of health factors, including lung function and quality of life, according to data presented at ATS 2022.
Read More
Study Evaluates Inhaled Nitric Oxide for COVID-19
Researchers assessed outcomes of INOmax inhaled nitric oxide for COVID-19 patients hospitalized with mild-to-moderate ARDS.
Read More
Judge: Praxair Did Not Infringe Mallinckrodt Patents
A judge in Delaware ruled that Praxair, which is seeking a generic version of the INOmax inhaled nitric oxide therapy, did not infringe on patents held by Mallinkrodt Inc.
Read More
RT Products Archive
RT’s product archive includes content on respiratory therapy products.
Read More